Suppr超能文献

脂肪酸造粒作为开发控释多颗粒剂型的连续过程。

Prilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms.

作者信息

Vervaeck A, Saerens L, De Geest B G, De Beer T, Carleer R, Adriaensens P, Remon J P, Vervaet C

机构信息

Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium.

出版信息

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):587-96. doi: 10.1016/j.ejpb.2013.02.003. Epub 2013 Mar 6.

Abstract

In this study, prilling was evaluated as a technique for the development of multiparticulate dosage forms using the fatty acids, stearic acid, and behenic acid as potential matrix formers to control the release of metoprolol tartrate (MPT), a highly water soluble drug. The in vitro drug release was dependent on the drug load, type of fatty acid, and pH of the dissolution medium. Higher drug loads resulted in faster release with behenic acid releasing drug over longer periods relative to stearic acid. The in vitro drug release was pH-dependent at low drug load with the release being slower at lower pH. Due to ionization of the fatty acid at pH 7.4, drug release was susceptible to the ionic strength at this pH value. Solid state characterization indicated that the crystalline state of the fatty acids was not affected by thermal processing via prilling, while the crystallinity of MPT was decreased. During storage, the amorphous MPT fraction recrystallized in the entire matrix. Drug release from behenic acid matrices was increased during storage at 40 °C; however, no polymorphism of behenic acid was detected. The bioavailability of MPT, after oral administration to dogs as prills containing 30% and 40% MPT using behenic acid as matrix former, was not significantly different from a commercial sustained release reference formulation, although the 40% MPT prills showed a burst release.

摘要

在本研究中,对造粒法进行了评估,该方法用于开发多颗粒剂型,使用脂肪酸(硬脂酸和山嵛酸)作为潜在的基质形成剂来控制酒石酸美托洛尔(MPT,一种高水溶性药物)的释放。体外药物释放取决于药物载量、脂肪酸类型和溶出介质的pH值。较高的药物载量导致释放更快,与硬脂酸相比,山嵛酸在更长时间内释放药物。在低药物载量下,体外药物释放依赖于pH值,在较低pH值下释放较慢。由于脂肪酸在pH 7.4时发生离子化,药物释放在该pH值下易受离子强度的影响。固态表征表明,脂肪酸的结晶状态不受造粒热加工的影响,而MPT的结晶度降低。在储存期间,无定形MPT部分在整个基质中重结晶。在40℃储存期间,山嵛酸基质的药物释放增加;然而,未检测到山嵛酸的多晶型现象。以山嵛酸为基质形成剂,给犬口服含30%和40% MPT的造粒后,MPT的生物利用度与市售缓释参比制剂无显著差异,尽管40% MPT造粒显示出突释现象。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验